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A Therapeutic Approach to Erythrodermic Psoriasis: Report of a 
Case and a Discussion of Therapeutic Options 
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In this case report a patient with therapeutically recalcitrant 
erythrodermic psoriasis is presented. After various attempts with 
several major therapies in t his patient , the first substantia l 
improvement was achieved us ing the combination of cyclosporine 
and calcipotriol, followed by the combination of UVB and 
calcipotriol. The therapeutic options for severe psoriasis are 
discussed, and since combined a pproaches seem to be an attrac-
tive alternative for severe psoriasis, mechanisms of synergy of 
combined therapeutic approaches are hypothesised. Key words: 
calcipotriol; cyclosporine; UVB; combination therapy. 
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Erythrodermic psoriasis is a ra re but dramatic condition. As 
a result of a trigger of any kind, psoriasis can become unstable 
and can extend until the whole skin is erythematous and scaly. 
In general, systemic treatment of erythrodermic psoriasis is 
inevitable, and patients should be admitted at the inpatient 
department. 
Well-established therapeutic options for severe psoriasis, 
including erythrodermic psorias is, are methotrexate, acitretin 
and cyclosporine. However, the therapeutic response in 
patients with erythrodermic psoriasis may be variable and 
sometimes disappointing. The search for the appropriate 
therapy is time·consumjng. Often a combina tion of systemic 
a nd local therapies will provide the eventua l remedy for the 
patient after several weeks of in tensified supervision. 
The aim of this report is to present a case. indicating the 
therapeutic problems during treatment of erythrodermic 
psoriasis. 
CASE REPORT 
An 83-year·old erythrodermic man was admitted to our hospital. At 
dermatological investigation generalised erythema and extensive seal· 
ing was observed all over tbe body ( Fig. I) , face, scalp, palms and 
soles. Histopathological investigation of the skin showed a chronic, 
non·specific dermatitis without signs of lymphoma or psoriasis. At 
general investigat ion we saw a dyspnoeic man with oedema on both 
lower legs. The body weight was 63 kg. No enlarged lymphnodes were 
palpable. o additional abnormalities were observed except for pre· 
existent gallstones. Blood tests. X·thorax, ECG, CT-scan of thorax 
and abdomen, X-colon did not reveal any internal pathology. 
Especially no evidence existed for malignancy. Serum I ,25 (OH h 
vitamin 0 3 and 25 OH vitamin 0 3 were 70 pmoljl and 50 runol/ 1, 
respectively. which was in the normal range. 
The patient had had psoriasis vulgaris for 5 years. The condition 
could be controlled up to 6 months prior to admission. A first 
exacerbation was treated with tar·UVB and calcipotriol. but 4 months 
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later, the psoriasis flared again resulting in erythrodem1a. The patient 
was admitted to a hospital elsewhere and was treated with potent 
topical corticosteroids such as clobetasol 17-propionatc and different 
systemic therapies. each of these only for a short period. Acitretin 
had been given for 3 weeks. methotrexate for 2 weeks and oral 
corticosteroids also for 2 weeks, without any substantial improvement. 
No factors were found that could have triggered this exacerbation of 
psoriasis. There was no history of infections or malignancy. 
As the expression of psoriasis was extremely severe and unresponsive 
to various treatments, the patient was transferred to the university 
hospitaL We started therapy with acitretin (20 mg/day) and hydrocor· 
tisone ( 1% in petrolatum) topically. Water·salt·balance normalised: 
furosemide 40 mg daily was given to control oedema and dyspnoea. 
Protein loss due to scaling was compensated with the appropriate diet. 
After 4 days the dose of acitretin was increased to 30 mgfday. Since 
there was no improvement. cyclosporine (3 mg/ kg/day) was added 
after another 4 days. This resulted only in a minor improvement after 
3 weeks: subsequently the dose of cyclosporine was increased to 4 mg 
kg,day. After another week acitretin was stopped and cyclosporinc 
was again increased to 5 mgtkg/day. The skin condition in the patient 
still did not improve. Then it was decided to start local calcipotriol 
on the right side of the body whi lst continuing cyclosporine. The 
calcipotriol·treated side showed a remarkable improvement compared 
to the other side. which was treated with bland emollients (Fig. 2). 
After I week the whole body was treated on alternate days with 
calcipotriol twice daily up to 100 g per week. On the remaining days 
of the week bland emollients were applied. As the quantity of 
calcipotriol ointment approximated 100 g per week calcium and phos· 
phate in the serum were measured at weekly intervals. 
The condition of the skin improved markedly within 4 weeks. 
Meanwhile. after treatment with cyclosporine for 2 months. the serum 
creatinine increased and the patient developed a tremor or unknown 
origin, which could have been a side-effect of cyclosporine. These 
Fig. /. Erythrodermic skin and extensive scaling all over the body, at 
the moment of admission to hospital. 
Acta Derm Venereal (Stockh) 76 
66 C. J. M. l'an der Vleuten et al. 
Fig. 2. Remarkable improvement on the right side of the body, due 
to calcipotriol on this side combined with systemic cyclosporine. 
symptoms necessitated discontinuation of cyclosporinc. As an alternat-
i,·e to cyclosporine. phototherapy \\1th a lo" do~ UVB in combmauon 
with local calcipotriol was started. The patient responded well to thb 
treatment and was discharged from hospital in a reasonable condition 
after I month of phototherapy. Phototherapy in combination with 
local calcipotriol was continued at the out-patient department for 
about 4 months. So far the condition of the patient remains excellent, 
without any psoriatic lesion up till 6 months <lfler discharge from 
hospital. 
During the various treatments, apart from the transient increase of 
serum creatinine and the temporary tremor during cydosporine, no 
side-effects occurred. Serum calcium and pho~phate remained in the 
normal range. 
DISCUSS!O. 
Before deciding on the strategy of the treatment. the underlying 
cause of the erythroderma has to be established. Histo-
pathological investigation is not always specific (I). The 
history of a previous skin disease is an important clue to the 
diagnosis; 25% of the cases are associated with psoriasis. 
Drugs. neoplasia and eczema account for the majority of the 
other known causes. In a substantial part of the cases no 
obvious cause is found (2). In case the nosological identity of 
the erythroderma remains unknown. further internal investi-
gation is required to exclude paraneopla~ia ( 3 ). 
As erythroderma is a serious condition, fast improvement 
is urgently wanted. Topical treatments with potent cortico-
steroids may be useful; however. as the patient described in 
th is report had already been treated e lsewhere with potent 
corticosteroids (clobetasoll7-propionate), a weak steroid pre-
paration was prescribed in order to prevent systemic complica-
tions. Systemic treatment is often necessary but is sometimes 
changed if no response is observed after a few days. Also in 
the present case. various short treatments were initiated with-
out allowing a sufficienr treatment period for an anti-psoriatic 
result . One may argue that the period of 1-week acitretin 
monotherapy might have been too short to induce a significant 
improvement. However, the severity of the erythroderma 
required a fast therapeutical effect. hence the combined 
approach. 
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Combinations of the major therapies for psoriasis are an 
attractive option. since some combinations allow a lower do e 
than that used in monotherapy. \\hich reduces side-effects. 
The combination of methotrexate and etretinate is controver-
sial in view of hepatotoxicity ( 4.5 ): the combination of etreti-
nate and cyclospor ine has been used with success in psoriasis 
(6,7). From a theoret ical point of view. the immunosuppressive 
effect of cyclosporine and the d ifferentiatio n modulat ing effect 
of retinoids is a promising combination. Oral retinoids 
have also been combined successfully with UVB or PUVA 
(re-PUVA) (8,9). The combination of two immunosuppressive 
therapies like methotrexate and cyclosporine is not recom-
mended ( 10). 
Another practical approach is the combination of systemic 
and topical therapy. After various attempts with several major 
therapies in this patient, including the combination of cyclo-
sporine and acitretin , the firs t substantial improvement was 
ach ieved using the combination of caleipotriol and cyclospor-
ine. In the past emollients, ta rs and topical steroids have been 
used in combination with systemic therapies ( 11 ). Nowadays, 
the vitamin D 3 analogue calcipot riol is available. I ts beneficial 
effect as a monotherapy in mild to moderate chronic plaque 
psoriasis has been well established ( 12 ). However. calcipotriol 
might irritate the skin in about 20'''• of the patients (13 ). In 
particular patients with erythrodem1ic psoriasis are susceptible 
to low doses of irritants. On the other hand. patients with 
unstable and erythrodermic psoriasis have been reported to 
respond well to calcipotriol ( 14,15 ). ln the present case the 
maximum quantity of 100 g calcipotriol ointment per week 
was not exceeded. As serum vitamin 0 3 levels were no rmal. it 
was excluded that th is patient might have had a vi tamin 0 3 
deficiency. 
The skin is the site of production of vitamin 0 3 and target 
of its acti\'e metabolite: l:x,25-dihydroxy,·itamin 0 3 ( 16 ). 
Vitamin D 3 receptors. member of the steroid-hormone-
receptor super-family, are found in the epidermis ( 17). The 
therapeutic mode of action of' itamin 0 3 and its analogues in 
psoriasis is partly via these receptors. which regulate gene 
transcription. and partly through non-genomic mechanisms 
( 18 ). Calcipotriol inhibits proliferation and induces termina l 
differentiation in cultured human keratinocytes ( 19 ) . In l'il•o 
these effects are observed as well (20). lmmunomodulating 
effects of calcipotriol are also described: inhibition ofT-cell 
proliferation in response to interleukin I in PilrO (21) and 
reduction of interleukin 6 in a psoriatic plaque in 1·iro in 
re)ponse to calcipotriol ( 22 ). 
In literature both cyclosporinc ( 23) and l i'VB ( 24.25) have 
been combined successfully \\ith calcipotriol in psoriatic 
patients. In particular low-dose cyclosporine (2 mg kg day) in 
combination with calcipotriol proved to be an effective and 
safe approach (23). From a theoret ical point of view it is 
attractive to speculate that calcipotriol-cyclosporine is a useful 
combina tion. The modes of action of cyclosporine and 
I !>:,25-dihydroxyvitamin 0 3 and its analogues are thought to 
be complementary (26-28 ). Recently several investigators have 
demonstrated the synergistic effects of both anti-psoriatic 
therapies. Calcipotriol can potentiate the immunosuppressive 
effect of cyclosporine in mixtures of human lymphatic and 
epidermal cells (29). The effect of cyclosporine on interleukin 
2 is increased by calcitriol ( 26 28 ). On the other hand. the 
differential effect of both treatments on epidermis and immune 
system might explain the synergistic effect (30.31 ). When 
cyclosporine treatmen t was not possible anymore in o ur patient 
due to increase of serum creatinine. UVB in combination with 
calcipotriol was applied successfully. In literature there is still 
no clearness about synergy of UVB and calcipotriol in psoria~is 
(24,25). But the rema rkable effect of the combination in this 
patient suggests that in some cases synergism might occur. 
In the case of erythrodermic psoriasis, the therapeutic 
stra tegy often includes systemic treatment. Options are mono-
therapy with acitretin , cyclospo rine or m e tho trexate. The 
choice depends on indications and contraindications in the 
individual patient. In the present case of persisting erythro-
denna. combination therapy of cyclosporine plus calcipotriol 
and subsequently UVB plus calcipotrio l proved to be a success-
ful approach. 
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